Literature DB >> 22321914

Thrombo-prophylaxis in colorectal surgery: a National Questionnaire Survey of the members of the Association of Coloproctology of Great Britain and Ireland.

N Srinivasaiah1, R Arsalani-Zadeh, J R Monson.   

Abstract

AIM: Available guidelines from the National Institute for Health and Clinical Excellence (NICE) and the Association of Coloproctology of Great Britain and Ireland (ACPGBI) recommend combined (medical + mechanical) thrombo- prophylaxis. A Cochrane Library review recommends self-administered low-molecular-weight heparin (LMWH) for 2-3 weeks following surgery. In the light of the recent guidelines from the ACPGBI and NICE, we undertook a National Questionnaire Survey to assess current thrombo-prophylaxis practice among colorectal surgeons in the UK.
METHOD: A 10-item questionnaire was designed to enquire into the current management strategy of postoperative thrombo-prophylaxis. The postal questionnaire survey was sent to all 490 active consultant members of the ACPGBI.
RESULTS: Of the 490 questionnaires sent, 259 (52.8%) were returned fully completed. Among these, all (100%) respondents reported the routine use of thrombo-prophylaxis, with 243 (93.8%) following departmental guidelines. Combined medical and mechanical prophylaxis was used by 247 (95.40%) respondents. A small number - 12 (4.6%) - used medical prophylaxis only. LMWH was the preferred medical-prophylactic agent of 243 (93.8%) repondents. The majority, 176 (68%), started thrombo-prophylaxis on admission and stopped it at discharge. Seventy-one (27.4%) respondents recommended thrombo-prophylaxis after hospital discharge for an average duration of 4-6 weeks, preferring graduated compression stockings followed by LMWH.
CONCLUSION: The National Questionnaire Survey on thrombo-prophylaxis demonstrated a high degree of concordance with the available guidelines, except for thrombo-prophylaxis to be continued postoperatively for a period of 28 days/4 weeks.
© 2012 The Authors. Colorectal Disease © 2012 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321914     DOI: 10.1111/j.1463-1318.2012.02974.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

1.  Which Patients Require Extended Thromboprophylaxis After Colectomy? Modeling Risk and Assessing Indications for Post-discharge Pharmacoprophylaxis.

Authors:  Eliza W Beal; Dmitry Tumin; Jeffery Chakedis; Erica Porter; Dimitrios Moris; Xu-Feng Zhang; Mark Arnold; Alan Harzman; Syed Husain; Carl R Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

2.  Justifying Total Costs of Extended Venothromboembolism Prophylaxis After Colorectal Cancer Surgery.

Authors:  Ira L Leeds; Joseph K Canner; Sandra R DiBrito; Bashar Safar
Journal:  J Gastrointest Surg       Date:  2019-04-03       Impact factor: 3.452

3.  Thromboprophylaxis for lung cancer patients--multimodality assessment of clinician practices, perceptions and decision support tools.

Authors:  M Alexander; S Kirsa; M MacManus; D Ball; B Solomon; K Burbury
Journal:  Support Care Cancer       Date:  2014-02-27       Impact factor: 3.603

Review 4.  Extended venous thromboembolism prophylaxis after colorectal cancer surgery: the current state of the evidence.

Authors:  Tarik Sammour; Raaj Chandra; James W Moore
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

5.  Extended duration chemoprophylaxis for venous thromboembolism following abdominopelvic oncologic surgery.

Authors:  John Kanitra; John Holtrop; Ali Jawad; Richard Berri
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

6.  Population-Based Analysis of Adherence to Postdischarge Extended Venous Thromboembolism Prophylaxis After Colorectal Resection.

Authors:  Anudeep Mukkamala; John R Montgomery; Ana C De Roo; James W Ogilvie; Scott E Regenbogen
Journal:  Dis Colon Rectum       Date:  2020-07       Impact factor: 4.412

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.